BofA initiated coverage of Sutro Biopharma with a Buy rating and $12 price target. The firm believes luvelta, which is currently in Phase 3, could address high unmet need in platinum-resistant ovarian cancer. The analyst thinks the drug could treat up to 80% of PROC patients as the data suggest superior efficacy to stand of care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro announces initiation of randomized portion of REFRalphaME-O1 trial
- Sutro Biopharma price target lowered to $18 from $25 at Truist
- Sutro Biopharma price target lowered to $11 from $12 at Piper Sandler
- Sutro Biopharma 14.479M share Spot Secondary priced at $5.18
- Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering